GoHealth (GOCO) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.89 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -80.77%. A quarter ago, it was expected that this company would post earnings of $1.16 per share when it actually produced earnings of $2.41, delivering a surprise of 107.76%.Over the last four quarters, the company has surpassed ...

GoHealth (GOCO) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Company Participants John Shave - VP, IRVijay Kotte - Chief Executive OfficerBrendan Shanahan - Chief Financial OfficerDave Storms - Director of Equity Research Conference Call Participants Rob McGuire - Equity Research AnalystPatrick McCann - Equity Research AnalystJim Sidoti - Analyst Operator Good morning, and welcome to GoHealth's first quarter two thousand twenty five earnings conference call. My name is Tanya, and I'll be your operator for ...

GoHealth (GOCO) Q1 2025 Earnings Call May 13, 2025 08:00 AM ET Speaker0 Good morning, and welcome to GoHealth's first quarter two thousand twenty five earnings conference call. My name is Tanya, and I'll be your operator for today's call. Currently, all participants are in a listen only mode. Following the prepared remarks, we will conduct a question and answer session. As a reminder, this conference is being recorded. I would now like to turn the call over to John Shave, Vice President of Investor Relation ...

Financial Performance - GoHealth's Q1 2025 revenue increased to $221 million, a 19% increase compared to $1856 million in Q1 2024[11] - Adjusted EBITDA for Q1 2025 was $421 million, a 56% increase from $269 million in Q1 2024[11] - Cash flow from operations improved significantly, from -$124 million in Q1 2024 to $125 million in Q1 2025, a 199% increase[14] - Ending commissions receivable (current and non-current) increased by 19%, from $8431 million on March 31, 2024, to $10006 million on March 31, 2025[14] - Adjusted EBITDA margin increased from 145% to 190%[23] Unit Economics - Sales per submission decreased by 15%, from $856 in Q1 2024 to $724 in Q1 2025[16] - Direct operating cost per submission improved by 18%, decreasing from $640 in Q1 2024 to $522 in Q1 2025[16] Non-GAAP Measures - The company uses non-GAAP financial measures like EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin to evaluate business performance[7] - Adjusted EBITDA is calculated by adjusting EBITDA for items like severance costs, share-based compensation, professional services, operating lease impairment, and legal fees[7, 23]

Financial Performance - First quarter 2025 net revenues reached $221.0 million, a 19.1% increase from $185.6 million in the prior year period[4] - The net loss for the first quarter 2025 was $9.8 million, reflecting a 54.2% improvement compared to a net loss of $21.3 million in the prior year period[4] - Adjusted EBITDA for the first quarter 2025 was $42.1 million, a 56.4% increase from $26.9 million in the prior year period[4] - Net revenues for Q1 2025 reached $220,972,000, a 19.1% increase from $185,600,000 in Q1 2024[19] - The company reported a net loss of $9,786,000 for Q1 2025, an improvement of 54.2% compared to a net loss of $21,346,000 in Q1 2024[19] - Adjusted EBITDA for Q1 2025 was $42,060,000, compared to $26,894,000 in Q1 2024, reflecting a significant increase[20] - The net income (loss) margin improved to (4.4)% in Q1 2025, compared to (11.5)% in Q1 2024[20] Operational Metrics - Submissions in the first quarter 2025 totaled 303,026, marking a 40.2% increase from 216,148 submissions in the prior year period[4] - The number of submissions increased by 40.2%, reaching 303,026 in Q1 2025, compared to 216,148 in Q1 2024[24] - Sales per submission decreased to $724 in Q1 2025, down 15.4% from $856 in Q1 2024[24] - Direct operating cost per submission improved to $522, an 18.4% decrease from $640 in the prior year period[4] - Direct operating cost per submission improved to $522 in Q1 2025, a reduction of 18.4% from $640 in Q1 2024[24] Revenue Sources - The company experienced a significant increase in commission revenue, which rose to $167,109,000 from $79,733,000 year-over-year[22] - Commissions receivable - current decreased to $207,443,000 as of March 31, 2025, down from $320,399,000 at the end of 2024[23] Strategic Initiatives - GoHealth launched GoHealth Protect, expanding its product offerings into guaranteed acceptance life insurance[4] - The company aims to enhance cash flow generation and reduce acquisition costs through the scaling of the new life insurance offering[3] - Investments in high-return initiatives are expected to drive continued momentum in future quarters[3] - The company is focused on refining its platform and technology to improve consumer experience and outcomes[3] - GoHealth's proprietary technology platform leverages machine-learning algorithms to match health plans to consumer needs[7]

Core Viewpoint - GoHealth, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a False Claims Act complaint filed by the U.S. Department of Justice against several health insurance companies, including GoHealth [1][2]. Group 1: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against GoHealth on behalf of its stockholders [1]. - The DOJ's complaint alleges that from 2016 to at least 2021, GoHealth and other insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments into Medicare Advantage plans [2]. Group 2: Stock Market Impact - Following the announcement of the DOJ's lawsuit, GoHealth's stock price dropped by $1.09 per share, representing a decline of 10.35%, closing at $9.44 per share on May 1, 2025 [2].

Core Viewpoint - GoHealth, Inc. firmly denies allegations made by the Government in a lawsuit regarding its compliance with Medicare Advantage regulations and emphasizes its commitment to serving beneficiaries' needs [1][2][4]. Group 1: Compliance and Allegations - GoHealth asserts that it has complied with laws governing payments by Medicare Advantage carriers to brokers and denies receiving kickbacks or placing beneficiaries in suboptimal plans due to compensation [2]. - The company expresses disappointment over the Government's pursuit of claims against it, highlighting its efforts to advance the interests of the Medicare Advantage program [1][4]. Group 2: Commitment to Beneficiaries - GoHealth has a notable history of enrolling special needs beneficiaries, with 35% of its enrollees being from this population, compared to 17% in the overall Medicare Advantage population [3]. - The company has implemented programs like the Low Income Subsidy (LIS) team to help beneficiaries enroll in government programs at no charge, demonstrating its focus on prioritizing beneficiaries' needs [3]. Group 3: Company Overview - GoHealth is a leading health insurance marketplace focused on Medicare, utilizing a technology platform that leverages machine-learning algorithms to match health plans to consumer needs [8]. - The company aims to provide peace of mind to consumers in their healthcare decisions, facilitating the enrollment of millions in Medicare plans since its inception [8].

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against GoHealth, Inc. (“GoHealth” or the “Company”) (NASDAQ:GOCO). The investigation concerns whether GoHealth and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a complaint against insurance broker organizations, including GoHealth ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GoHealth, Inc. ("GoHealth" or the "Company") (NASDAQ: GOCO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether GoHealth and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 1, 2025, the U.S. De ...

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of GoHealth, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - The U.S. Department of Justice filed a False Claims Act complaint against GoHealth and other health insurance companies, alleging that from 2016 to at least 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments into Medicare Advantage plans [3] - Following the DOJ's lawsuit announcement, GoHealth's stock price dropped by $1.09 per share, a decrease of 10.35%, closing at $9.44 per share on May 1, 2025 [3]